Monument Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$73.4K
- Investors
-
13
Monument Therapeutics General Information
Description
Developer of novel drugs intended to treat serious diseases of the central nervous system. The company's approach utilizes proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, enabling researchers to focus on the advancement of neuroscience drugs in areas of unmet medical needs.
Contact Information
Website
www.monumenttx.comCorporate Office
- Menzies LLP One Express
- 1 George Leigh Street
- Manchester M4 5DL
- England, United Kingdom
Corporate Office
- Menzies LLP One Express
- 1 George Leigh Street
- Manchester M4 5DL
- England, United Kingdom
Monument Therapeutics Timeline
Monument Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Accelerator/Incubator | 09-Feb-2026 | $73.4K | Completed | Clinical Trials - Phase 2 | ||
| 4. Later Stage VC | 25-Feb-2025 | Completed | Clinical Trials - Phase 2 | |||
| 3. Seed Round | 15-Dec-2021 | Completed | Clinical Trials - Phase 2 | |||
| 2. Grant | 01-Nov-2020 | $636K | Completed | Clinical Trials - Phase 2 | ||
| 1. Early Stage VC | Cancelled | Startup |
Monument Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| A1 Ordinary | ||||||||
| A2 Ordinary | ||||||||
| A2 Ordinary | 117,735 | $0.013563 | $26.07 | $26.07 | 1x | $26.07 | 26.67% | |
| A1 Ordinary | 79,171 | $0.013563 | $26.07 | $26.07 | 1x | $26.07 | 17.94% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Monument Therapeutics Comparisons
Industry
Financing
Details
Monument Therapeutics Competitors (78)
One of Monument Therapeutics’s 78 competitors is Castle Creek Biosciences, a Venture Capital-Backed company based in Exton, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Castle Creek Biosciences | Venture Capital-Backed | Exton, PA | ||||
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Lexeo Therapeutics | Formerly VC-backed | New York, NY | ||||
| Genevant | Corporate Backed or Acquired | Vancouver, Canada | ||||
| etherna | Formerly VC-backed | Niel, Belgium |
Monument Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Monument Therapeutics Patents
Monument Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202208507-D0 | Fibrate compositions for treating inflammation and neuroinflammation | Active | 14-Mar-2022 | ||
| GB-2616923-A | Fibrate compositions for treating inflammation and neuroinflammation | Active | 14-Mar-2022 | ||
| WO-2023174941-A1 | Fibrate compositions for treating inflammation and neuroinflammation | Inactive | 14-Mar-2022 | A61K31/216 |
Monument Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Monument Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| One Mind | Accelerator/Incubator | |||
| ACF Investors | Venture Capital | Minority | ||
| Cambridge Angels | Angel Group | Minority | ||
| Manchester Tech Trust Angels | Angel Group | Minority | ||
| Meltwind Advisory | Venture Capital | Minority |
Monument Therapeutics FAQs
-
When was Monument Therapeutics founded?
Monument Therapeutics was founded in 2019.
-
Where is Monument Therapeutics headquartered?
Monument Therapeutics is headquartered in Manchester, United Kingdom.
-
What is the size of Monument Therapeutics?
Monument Therapeutics has 7 total employees.
-
What industry is Monument Therapeutics in?
Monument Therapeutics’s primary industry is Drug Discovery.
-
Is Monument Therapeutics a private or public company?
Monument Therapeutics is a Private company.
-
What is the current valuation of Monument Therapeutics?
The current valuation of Monument Therapeutics is .
-
What is Monument Therapeutics’s current revenue?
The current revenue for Monument Therapeutics is .
-
How much funding has Monument Therapeutics raised over time?
Monument Therapeutics has raised $8.64M.
-
Who are Monument Therapeutics’s investors?
One Mind, ACF Investors, Cambridge Angels, Manchester Tech Trust Angels, and Meltwind Advisory are 5 of 13 investors who have invested in Monument Therapeutics.
-
Who are Monument Therapeutics’s competitors?
Castle Creek Biosciences, NGM Biopharmaceuticals, Lexeo Therapeutics, Genevant, and etherna are some of the 78 competitors of Monument Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
